Conditions: Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer or Endometrial Cancer Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
Keywords: Ovarian cancer HER-2 negative breast cancer Breast cancer Fallopian tube cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 41
Healthy volunteers: no

Brief summary:
This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial of MM-121 in combination with paclitaxel using a "3+3" design.

Detailed description:
Successive cohorts of three or more patients were treated at escalating doses until a maximum tolerated dose/recommended phase 1 dose was identified. Once the maximum tolerated dose was identified, an Expansion Cohort was enrolled at that dose to further characterize safety and to explore pharmacodynamic endpoints.

Arms:
arm 1: Escalating doses of MM-121 given IV QW in combination with paclitaxel at standard dose of 80 mg/m2 IV QW

Interventions: intervention 1: MM-121 intervention 2: Paclitaxel
Intervention descriptions: intervention 1: increasing doses of MM-121 IV QW intervention 2: Paclitaxel - 80 mg/m2 IV QW

Protocol document: